Learn more →
Back to Expert Scholars
melanoma / melanomaMelanoma Immunotherapy

Ryan Sullivan

瑞安·沙利文

MD

🏢Massachusetts General Hospital, Harvard Medical School(麻省总医院,哈佛医学院)🌐USA

Associate Professor of Medicine, Co-Director of Melanoma Program医学副教授,黑色素瘤项目联合主任

55
h-index
3
Key Papers
4
Awards
3
Key Contributions

👥Biography 个人简介

Ryan Sullivan is a melanoma oncologist at Massachusetts General Hospital specializing in BRAF/MEK inhibitor combinations and overcoming drug resistance. His translational research bridges laboratory discoveries on resistance mechanisms to innovative clinical trial designs for advanced melanoma.

Share:

🧪Research Fields 研究领域

Melanoma黑色素瘤
BRAF/MEK Inhibitor CombinationsBRAF/MEK抑制剂联合
Drug Resistance耐药机制
Combination Immunotherapy联合免疫治疗

🎓Key Contributions 主要贡献

BRAF/MEK Inhibitor Drug Resistance

Elucidated reactivation of the MAPK pathway and alternative resistance mechanisms to BRAF/MEK inhibitors in melanoma, guiding development of triplet therapy and intermittent dosing strategies.

Triplet Targeted-Immunotherapy Combinations

Pioneered clinical trials combining BRAF/MEK inhibitors with PD-1 checkpoint blockade, investigating sequencing strategies to maximize antitumor immunity and delay resistance.

Translational Biomarker Research

Developed and validated circulating tumor DNA and immunohistochemical biomarkers for predicting and monitoring response to targeted therapy and immunotherapy in melanoma patients.

Representative Works 代表性著作

[1]

Intermittent BRAF Inhibition in BRAF V600E Melanoma: A Phase 2 Trial

Nature Medicine (2019)

Demonstrated that intermittent dosing of BRAF inhibitors can delay acquired resistance and extend benefit.

[2]

Atezolizumab plus Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma (IMspire150)

The Lancet (2020)

Phase III trial of triple combination immunotherapy plus targeted therapy showing improved PFS.

[3]

Mechanisms of Resistance to BRAF Inhibitors in Melanoma

Journal of Clinical Oncology (2015)

Comprehensive review defining clinical and genomic mechanisms underpinning targeted therapy resistance in melanoma.

🏆Awards & Recognition 奖项与荣誉

🏆ASCO Young Investigator Award
🏆Melanoma Research Foundation Established Investigator Award
🏆Society for Melanoma Research Best Abstract Award
🏆MGH Clinical Research Excellence Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 瑞安·沙利文 的研究动态

Follow Ryan Sullivan's research updates

留下邮箱,当我们发布与 Ryan Sullivan(Massachusetts General Hospital, Harvard Medical School)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment